Abstract: Disclosed herein are methods for selecting a patient suffering from fungal-associated intestinal inflammation for treatment with an IL-1 pathway inhibitor, including inflammasome-blocking drugs based on the presence of candidalysin-secreting C. albicans strains in gut tissue.

Abstract: The clinical diagnosis and monitoring of patients with neurological conditions may be established through behavioral examinations, assessments or evaluations, or neuroimaging scans. The system and methods described herein diagnose the cognitive function of a subject by measuring the neural response of the subject to one or more naturalistic sensory stimuli. The system measures the subject's sensory evoked response to the naturalistic sensory stimuli by computing the statistical comparison between the subject's neural signal and either the raw stimulus signal or the stimulus' signal envelope. A latency value, or other signal feature, is extracted from the subject's sensory evoked response and a diagnosis of the subject's cognitive function is then made based on the identified latency value or other extracted signal feature.

Abstract: Systems and methods herein provide for adaptive subband compression of power signals in a power system. In one embodiment, a system includes an encoder is operable to partition sensor measurements into frequency subbands (e.g., including an interharmonic subband), centered at integer multiples of the power system's fundamental frequency (e.g., 50 Hz or 60 Hz). The encoder may also be operable to detect active subbands, and to compress the at least one active subband. The system also includes a data concentrator operable to transmit the at least one compressed subband to a processor for analysis. The system also includes a decoder at a processing location (a substation, a concentrator, or the control center) operable to parse the compressed waveforms into subbands, to interpolate and decompress at least one compressed subband, and to synthesize the decompressed subbands as an approximation of the original waveform (e.g., subject to reconstruction error requirements).

Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: The present invention relates to, inter alia, a microfluidic device for capturing target cells and analyzing genomic DNA isolated from the target cells while under flow conditions. The microfluidic device includes a cell microchannel and a nucleic acid microchannel that intersect in an orthogonal manner, thereby forming a cell capture intersection region. The microfluidic device also includes a cell capture array and a nucleic acid entanglement array. The cell capture array includes a plurality of cell capturing micropillars and is located in the cell capture intersection region. The nucleic acid entanglement array includes a plurality of nucleic acid entanglement micropillars that function to physically entangle and maintain thereon genomic DNA isolated from the one or more target cell, and is located in a portion of the nucleic acid microchannel that is adjacent to and downstream of the cell capture intersection region. Methods of using the microfluidic device are also disclosed.

Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.

Abstract: This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.

Abstract: The present invention relates to a RNA molecule comprising a first ribozyme, a first ligation sequence, an effector molecule, a second ligation sequence, and a second ribozyme. Methods of producing circular RNA molecules and treatment methods are also disclosed.

Abstract: The present disclosure may be embodied as methods and/or systems for non-contact measuring of an on-body and/or inside-body motion of an individual. A sensing signal is provided within a near-field coupling range of a motion to be measured. In this way, a measurement signal may be generated as the sensing signal modulated by the motion. The sensing signal may be an ID-modulated signal. In some embodiments, the sensing signal is a backscattered RFID link provided a wireless tag. A downlink signal may be provided to power the wireless tag. The sensing signal may be a harmonic of the downlink signal. The measurement signal is detected. The motion is measured based on the measurement signal. The measurement signal may be detected as far-field radiation after transmission through a source of the motion. The measurement signal may be detected as reflected from a source of the motion as antenna reflection.

Abstract: Methods of nanomanufacturing based on continuous additive nanomanufacturing at fluid interfaces (CANFI). This approach is a fabrication technique that involves, for example, photocuring or “printing” self-assembled layers. CANFI presents a fabrication capability with significant transformative potential improve (i) the spatial resolution, (ii) the speed, and (iii) the range of material compositions that can be printed. Various articles of manufacture can be made using the methods.

Abstract: The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

Abstract: Apparatus for applying Transcranial Magnetic Stimulation (TMS) to an individual, wherein the apparatus comprises: a head mount for disposition on the head of an individual; and a plurality of magnet assemblies for releasable mounting on the head mount, wherein each of the magnet assemblies comprises a permanent magnet, and at least one of (i) a movement mechanism for moving the permanent magnet and/or (ii) a magnetic shield shutter mechanism, for selectively providing a rapidly changing magnetic field capable of inducing weak electric currents in the brain of an individual so as to modify the natural electrical activity of the brain of the individual; wherein the number of magnet assemblies mounted on the head mount, their individual positioning on the head mount, and their selective provision of a rapidly changing magnetic field is selected so as to allow the spatial, strength and temporal characteristics of the magnetic field to be custom tailored for each individual, whereby to provide individual-specific

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3, R4, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: Methods, systems and programs for denoising a signal using an undecimated discrete wavelet transformation are provided. The methods use signal location windows. The signal location windows may be used before or after thresholding. When signal location windows are used after thresholding coefficients within the signal location windows may be restored to their original values. When signal location windows are used before thresholding, coefficients within the signal location windows may be unchanged by the thresholding. The signal location windows may be used only on a subset of decomposition levels that are thresholded. The signal location windows may be used on both the Detail components and the highest decomposition level for thresholding of the Approximation component.

Abstract: Systems and methods herein provide for a tunable resonator. In one embodiment, a tunable resonator includes a transmission line comprising at least two inductor segments and a tap between each of the at least two inductor segments. The resonator also includes one less switch than a number of the at least two inductor segments on the transmission line. Each switch is coupled to one of the taps. And, each switch is operable to decouple at least one of the at least two inductor segments in the transmission line by shunting at least a portion of the transmission line to ground to change a resonant frequency of the transmission line.

Abstract: A method for treating a subject having or likely to develop a neurodegenerative disease, wherein the subject is administered a pharmaceutically effective amount of a compound within the generic structure (1) wherein R1 is either —R or —SR, wherein R is a hydrocarbon group containing 1-20 carbon atoms and optionally containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur; and R2 is selected from the group consisting of —OR?, —OPO32?, and —OC(O)R?, wherein R? is a hydrogen atom or a hydrocarbon group containing 1-6 carbon atoms; and wherein Formula (1) may include pharmaceutically acceptable salts, solvates, and polymorphs thereof, and wherein the subject may be identified as positive, before or during treatment, for at least one marker, including, for example, amyloid plaques, neurofibrillary tangles, decline in brain glucose metabolism, decline in thiamine diphosphate-dependent enzyme activity, and increase in advanced glycation end products.

Abstract: Lithium ion batteries, electrodes, nanofibers, and methods for producing same are disclosed herein. Provided herein are batteries having (a) increased energy density; (b) decreased pulverization (structural disruption due to volume expansion during lithiation/de-lithiation processes); and/or (c) increased lifetime. In some embodiments described herein, using high throughput, water-based electrospinning process produces nanofibers of high energy capacity materials (e.g., ceramic) with nanostructures such as discrete crystal domains, mesopores, hollow cores, and the like; and such nanofibers providing reduced pulverization and increased charging rates when they are used in anodic or cathodic materials.

Abstract: Conducting coatings disposed on a metal member. The conducting coatings may have a desired texture and provide homoepitaxial or heteroepitaxial coating of an electrodeposited layer. A conducting coating may be formed by applying a shear force during deposition of the conducting coating. The conducting coatings may be used in anodes of various electrochemical devices. A conducting coating, which may be part of an electrochemical device, may have an electrochemically deposited layer disposed on at least a portion of a surface of the conducting coating. The electrochemically deposited layer may be reversibly electrochemically deposited.

Abstract: A method providing direct access to porous three-dimensionally (3D) continuous polymer network structures and shapes by combining BCP-resol co-assembly with CO2 laser-induced transient heating. The CO2 laser source transiently heats the BCP-directed resol hybrid films to high temperatures at the beam position, inducing locally controlled resol thermopolymerization and BCP decomposition in ambient conditions. This enables shaping of BCP-directed porous resin structures with tunable 3D interconnected pores in a single process. Pore size can be varied from 10 nm to about 600 nm.

Abstract: Provided herein are high throughput continuous or semi-continuous reactors and processes for manufacturing graphenic materials, such as graphene oxide. Such processes are suitable for manufacturing graphenic materials at rates that are up to hundreds of times faster than conventional techniques, have little batch-to-batch variation, have a high degree of tunability, and have excellent performance characteristics.